OxFORD Asset Management LLP Takes $3.78 Million Position in Zogenix, Inc. (ZGNX)

OxFORD Asset Management LLP purchased a new stake in shares of Zogenix, Inc. (NASDAQ:ZGNX) in the third quarter, according to its most recent filing with the SEC. The firm purchased 125,084 shares of the company’s stock, valued at approximately $3,779,000. OxFORD Asset Management LLP owned 0.37% of Zogenix at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. TIAA CREF Investment Management LLC raised its position in shares of Zogenix by 0.9% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 66,610 shares of the company’s stock worth $966,000 after purchasing an additional 608 shares during the last quarter. Voya Investment Management LLC grew its stake in Zogenix by 13.5% in the 2nd quarter. Voya Investment Management LLC now owns 14,147 shares of the company’s stock worth $205,000 after acquiring an additional 1,686 shares during the period. Bank of New York Mellon Corp grew its stake in Zogenix by 2.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 105,926 shares of the company’s stock worth $1,536,000 after acquiring an additional 2,467 shares during the period. Alliancebernstein L.P. grew its stake in Zogenix by 16.3% in the 2nd quarter. Alliancebernstein L.P. now owns 17,812 shares of the company’s stock worth $258,000 after acquiring an additional 2,500 shares during the period. Finally, Metropolitan Life Insurance Co. NY grew its stake in Zogenix by 17.0% in the 1st quarter. Metropolitan Life Insurance Co. NY now owns 19,734 shares of the company’s stock worth $214,000 after acquiring an additional 2,864 shares during the period. Hedge funds and other institutional investors own 73.43% of the company’s stock.

Zogenix, Inc. (NASDAQ:ZGNX) opened at $36.20 on Friday. Zogenix, Inc. has a 12 month low of $7.70 and a 12 month high of $42.60. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.23.

In other news, major shareholder Life Sciences Maste Perceptive bought 300,000 shares of the stock in a transaction that occurred on Tuesday, October 3rd. The shares were acquired at an average cost of $37.50 per share, for a total transaction of $11,250,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 5.00% of the company’s stock.

Several analysts have commented on the stock. JMP Securities began coverage on shares of Zogenix in a research note on Monday, November 27th. They issued an “outperform” rating and a $56.00 target price for the company. Mizuho restated a “buy” rating and issued a $51.00 target price on shares of Zogenix in a research note on Wednesday, November 8th. Leerink Swann reaffirmed an “outperform” rating and set a $50.00 price objective (up previously from $20.00) on shares of Zogenix in a research report on Monday, October 2nd. ValuEngine raised shares of Zogenix from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $55.00 price objective (up previously from $26.00) on shares of Zogenix in a research report on Friday, September 29th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $42.67.

ILLEGAL ACTIVITY NOTICE: “OxFORD Asset Management LLP Takes $3.78 Million Position in Zogenix, Inc. (ZGNX)” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/12/08/oxford-asset-management-llp-takes-3-78-million-position-in-zogenix-inc-zgnx.html.

Zogenix Profile

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Institutional Ownership by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply